stockportfolio.pro
Stocks / NTLA vs ZYME
NTLA vs ZYME
Intellia Therapeutics, Inc. and Zymeworks Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Intellia Therapeutics, Inc. (NTLA) | Zymeworks Inc. (ZYME) | |
|---|---|---|
| Market cap | $1.7B | $1.7B |
| Revenue (latest FY) | $67.67M | $105.97M |
| Net income (latest FY) | $-412.69M | $-81.13M |
| Revenue growth (5y CAGR) | 3.1% | 22.2% |
| Net margin | -609.9% | -76.6% |
| Return on equity | -61.5% | -30.2% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open NTLA — free Open ZYME — freeFrequently asked questions
Which is bigger, NTLA or ZYME?
Intellia Therapeutics, Inc. is larger by market capitalization — $1.7B versus $1.7B.
Which grows faster, NTLA or ZYME?
Over the last five fiscal years, Zymeworks Inc. grew revenue faster — 22.2%/yr versus 3.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.